• About us
    • Our Story
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Our Products
    • Sibnayal®
    • Other Products
  • R&D
  • Disease Focus Area
    • Distal Renal Tubular Acidosis (dRTA)
    • Cystinuria
  • Investors
    • Investor Relations
    • Management Team
    • Press Releases
    • Events & Presentations
    • Analyst Coverage
    • Stock Information
    • Financial Information
    • Investors FAQs
  • Contact Us
  • EN
    • FR

E-mail alerts subscription

  • Investor Relations
  • Management Team
    • Letter from the CEO
    • Management
    • Board of Directors – Gouvernance
    • Governance
  • Press Releases
  • Events & Presentations
  • Analyst Coverage
  • Stock Information
  • Financial Information
  • Investors FAQs
  • Relations Investisseurs
  • Équipe de direction
    • Message du DG
    • Équipe de Direction
    • Conseil d’Administration
    • Gouvernance
  • Communiqués de presse
  • Événements & présentations
  • Analystes
  • L’action Advicenne
  • Information Financière
  • FAQ Investisseurs

Please subscribe below to receive Advicenne’s latest investor updates.



    Toolkit

    Annual Meeting
    Information Request
    Corporate Presentation

    Email Alert

    Sign up to join Advicenne’s Press Releases diffusion list

    Sign up

    Contacts

    Advicenne
    262, Rue du Faubourg Saint Honoré
    75008 Paris – FRANCE
    Telephone: +33 (0)1 85 73 36 20
    Fax : +33 (0)1 85 73 36 29
    E-mail: contact@advicenne.com

    Financial Communications
    Ulysse Communication
    advicenne@ulysse-communication.com

    Boîte à outils

    Assemblée Générale
    Demande d'information
    Présentation Corporate

    Alerte Email

    Inscrivez-vous pour rejoindre la liste de diffusion des communiqués de presse d’Advicenne

    S'abonner

    Contacts

    Advicenne
    262, Rue du Faubourg Saint Honoré
    75008 Paris – FRANCE
    Telephone: +33 (0)1 85 73 36 20
    Fax : +33 (0)1 85 73 36 29
    E-mail: contact@advicenne.com

    Communication financière
    Ulysse Communication
    advicenne@ulysse-communication.com

    Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

    For more than 10 years, Advicenne has been dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults with rare renal diseases.

    At Advicenne we are dedicated to improving patients’ daily health and life. Our employees in France and the United States are committed to tackle the challenge of high unmet medical need to improve quality of life for patients and their caregivers.

    Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) was in 2021 approved by the European Medicine Agency and MHRA.

    Headquartered in Paris and listed on Euronext Growth (Euronext: ALDVI) since 2022. www.advicenne.com

    FC 100INT01-03.22

    Terms of use  |  Privacy policy  |  Caller Pricavy  |  Cookies policy  |  Sitemap

    Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

    Depuis plus de 10 ans, Advicenne se consacre au développement et à la mise sur le marché de nouveaux traitements innovants pour les personnes atteintes de maladies rénales rares. Notre ambition est de développer et d'apporter un traitement efficace et sûr aux patients souffrant de maladies rénales rares avec peu d'options thérapeutiques. Grâce à notre expertise dans la reformulation et l’administration des médicaments, nous pouvons développer des traitements innovants pour les enfants et les adultes souffrant de maladies rénales rares.

    Chez Advicenne, nous nous engageons à améliorer la santé et la vie quotidienne des patients. Nos collaborateurs en France et aux États-Unis s'engagent à relever le défi du besoin médical non satisfait pour améliorer la qualité de vie des patients et de leurs soignants.

    Sibnayal® (combinaison de citrate de potassium et de bicarbonate de potassium) a été approuvé en 2021 par l'Agence Européenne du Médicament (EMA) et l’Agence de réglementation des médicaments et des produits de santé du Royaume-Uni (MHRA).

    Siège social basé à Paris et coté sur Euronext Growth (Euronext: ALDVI) depuis 2022.

    FC 100INT01-03.22

    Conditions générales d’utilisation  |  Politique de confidentialité  |  Confidentialité des appels  |  Politique des cookies  |  Plan de site

    Please contact us on info@advicenne.com for our Corporate Presentation for 2022

    Veuillez nous contacter sur info@advicenne.com pour nous demander notre présentation corporate de 2022

    Your privacy is important to us
    We use cookies for our website advicenne.com to ensure it functions correctly, improve its performance and features, measure its audience/traffic and remember your browser preferences. You can configure and deactivate cookies by clicking on « Manage cookies ». Your preferences will be saved for 12 months. You can change your decision and modify your choices at any time by clicking « Manage cookies » at the bottom of each page or by going to our « Cookies policy » by clicking the link at the bottom of each page.

    By clicking on « Accept all » you consent to the deposit of cookies on your device.

    Accept all and access websiteManage cookiesReject all and access website
    Manage cookies

    Configuring cookies

    Click on the arrows to view the content and find out more about each cookie
    Reject all and access websiteSave my choices
    Cookies required for the Website to operate
    Always Enabled
    These cookies are required for the Website to operate and cannot be deactivated in our system. You can configure your browser to block these cookies or send you an alert about their existence but we cannot save your cookie preferences. These cookies do not contain any personal identification information.
    CookieDurationDescription
    cli_user_preference12 monthsThis Cookies is set by GDPR Cookie Consent plugin to save users preference of cookie consent
    cookielawinfo-checkbox-necessary12 monthsThis cookie is defined by the GDPR Cookie Consent plugin and records the user’s consent to "Necessary" category cookies.
    cookielawinfo-checkbox-performance12 monthsThis cookie is defined by the GDPR Cookie Consent plugin. The cookie is used to store the user’s consent to "Performance" category cookies.
    CookieLawInfoConsent12 monthsThis Cookies is set by GDPR Cookie Consent plugin to save users preference of cookie consent
    pll_language12 monthsThe pll _language cookie is used by Polylang to remember the language selected by the user when he comes back to visit again the website. This cookie is also used to get the language information when not available in another way.
    viewed_cookie_policy12 monthsThis cookie is defined by the GDPR Cookie Consent plugin and is used to store the user’s acceptance or rejection of cookies. It does not store any personal data.
    Performance cookies
    These enable us to assess how people use our Website. All information collected by these cookies is aggregated and anonymised. If you do not accept these cookies, we will not be informed about your visit to our Website..
    CookieDurationDescription
    _ga6 monthsRecords a unique identifier used to generate statistical data on how people use our Website.
    _ga_VQ7XH9070S6 monthsUsed for reporting and distinguishing a user and to calculate visitor, session and campaign data for site analytics to optimize the services the website can offer.
    _gat_gtag_UA_28487651_51 minuteWebsite ID code for tracking visits This cookie is deleted 1 minute after its creation.
    _gid1 dayRecords a unique identifier used to generate statistical data on how people use our Website. This cookie is deleted 1 day after its creation.